Last reviewed · How we verify
MONENSIN
Monensin, a marketed drug, operates by binding to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis and causing parasite death. Its key strength lies in its well-established mechanism of action and market presence, with a key composition patent expiring in 2028. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | MONENSIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Core Stabilization on Hand Trauma Outcomes (NA)
- Use of Allograft Adipose Matrix for Small Joint Arthritis of the Hand (EARLY_PHASE1)
- Total Contact Soft Cast in Diabetic Foot Ulcers (NA)
- Non-Contact Low-Frequency Ultrasound Vs Standard LaLonde Protocol for Fingertip Injury Wound Healing (NA)
- Management of Proximal Interphalangeal (PIP) Joint Injuries (NA)
- COMPARISON OF BANDAGE IN HAND EDEMA (NA)
- Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers (NA)
- Using an Adjustable Compression Garment for Secondary Upper Limb Lymphoedema (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MONENSIN CI brief — competitive landscape report
- MONENSIN updates RSS · CI watch RSS